Literature DB >> 10864196

Vinorelbine--a clinical review.

R K Gregory1, I E Smith.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2000        PMID： 10864196      PMCID： PMC2363259          DOI： 10.1054/bjoc.2000.1203

Source DB:  PubMed          Journal:  Br J Cancer        ISSN： 0007-0920            Impact factor:   7.640


× No keyword cloud information.
  55 in total

1.  Experimental antitumor activity of Navelbine.

Authors:  S Cros; M Wright; M Morimoto; H Lataste; J P Couzinier; A Krikorian
Journal:  Semin Oncol       Date:  1989-04       Impact factor: 4.929

Review 2.  The effect of antimicrotubule agents on signal transduction pathways of apoptosis: a review.

Authors:  L G Wang; X M Liu; W Kreis; D R Budman
Journal:  Cancer Chemother Pharmacol       Date:  1999       Impact factor: 3.333

3.  Navelbine: an ultrastructural study of its effects.

Authors:  M R Paintrand; I Pignot
Journal:  J Electron Microsc (Tokyo)       Date:  1983

4.  Microtubule formation in vitro in solutions containing low calcium concentrations.

Authors:  R C Weisenberg
Journal:  Science       Date:  1972-09-22       Impact factor: 47.728

5.  Pharmacokinetics of vinorelbine in man.

Authors:  P Marquet; G Lachatre; J Debord; B Eichler; F Bonnaud; G Nicot
Journal:  Eur J Clin Pharmacol       Date:  1992       Impact factor: 2.953

6.  Pharmacokinetic and preliminary metabolic fate of navelbine in humans as determined by high performance liquid chromatography.

Authors:  F Jehl; E Quoix; D Leveque; G Pauli; F Breillout; A Krikorian; H Monteil
Journal:  Cancer Res       Date:  1991-04-15       Impact factor: 12.701

7.  Pharmacokinetics of a new anticancer drug, navelbine, in patients. Comparative study of radioimmunologic and radioactive determination methods.

Authors:  P Boré; R Rahmani; J van Cantfort; C Focan; J P Cano
Journal:  Cancer Chemother Pharmacol       Date:  1989       Impact factor: 3.333

8.  [Myocardial infarction and vinorelbine. Report of a case].

Authors:  C Dubos; J N Prévost; J Brun; P Rousselot
Journal:  Rev Mal Respir       Date:  1991       Impact factor: 0.622

9.  A phase II study of Navelbine (vinorelbine) in the treatment of non-small-cell lung cancer.

Authors:  A Depierre; E Lemarie; G Dabouis; G Garnier; P Jacoulet; J C Dalphin
Journal:  Am J Clin Oncol       Date:  1991-04       Impact factor: 2.339

10.  Radioimmunoassay and preliminary pharmacokinetic studies in rats of 5'-noranhydrovinblastine (navelbine).

Authors:  R Rahmani; M Martin; J Barbet; J P Cano
Journal:  Cancer Res       Date:  1984-12       Impact factor: 12.701
View more
  27 in total

1.  Biweekly vinorelbine and tegafur/uracil in patients with metastatic breast cancer previously treated with anthracyclines and taxanes: GEICAM 2000-02 phase II study.

Authors:  Antonio Antón; Agustí Barnadas; Jesús Florián; Nuria Ribelles; María Lomas; Juan Lao; Ana González-Quintás; Mireia Margelí; Ana Belén Paules; Javier Gayo; Manuel Ramos
Journal:  Clin Transl Oncol       Date:  2011-04       Impact factor: 3.405

2.  The challenge of using biomarkers and molecularly targeted drugs to improve cure rate in early stage non-small cell lung cancer.

Authors:  Nevin Murray
Journal:  J Thorac Dis       Date:  2015-03       Impact factor: 2.895

3.  Past, present, and future challenges in breast cancer treatment.

Authors:  George W Sledge; Eleftherios P Mamounas; Gabriel N Hortobagyi; Harold J Burstein; Pamela J Goodwin; Antonio C Wolff
Journal:  J Clin Oncol       Date:  2014-06-02       Impact factor: 44.544

4.  Synthesis of C-15 vindoline analogues by palladium-catalyzed cross-coupling reactions.

Authors:  Peter D Johnson; Jeong-Hun Sohn; Viresh H Rawal
Journal:  J Org Chem       Date:  2006-09-29       Impact factor: 4.354

Review 5.  Vinorelbine: a review of its use in elderly patients with advanced non-small cell lung cancer.

Authors:  Monique P Curran; Greg L Plosker
Journal:  Drugs Aging       Date:  2002       Impact factor: 3.923

Review 6.  Vincristine-induced peripheral neuropathy in pediatric cancer patients.

Authors:  Erika Mora; Ellen M Lavoie Smith; Clare Donohoe; Daniel L Hertz
Journal:  Am J Cancer Res       Date:  2016-11-01       Impact factor: 6.166

7.  A phase II trial of vinorelbine and intensive temozolomide for patients with recurrent or progressive brain metastases.

Authors:  Fabio M Iwamoto; Antonio M Omuro; Jeffrey J Raizer; Craig P Nolan; Adília Hormigo; Andrew B Lassman; Igor T Gavrilovic; Lauren E Abrey
Journal:  J Neurooncol       Date:  2007-11-07       Impact factor: 4.130

8.  Gemcitabine plus vinorelbine chemotherapy regimens: a pharmacokinetic study of alternate administration sequences.

Authors:  Luigi Cattel; Mario Airoldi; Roberto Passera; Elga Cagliero; Barbara Stella; Franca Goffredo
Journal:  Pharm World Sci       Date:  2004-08

9.  Oral Capecitabine-Vinorelbine is Associated with Longer Overall Survival When Compared to Single-Agent Capecitabine in Patients with Hormone Receptor-Positive Advanced Breast Cancer.

Authors:  Claudio Vernieri; Michele Prisciandaro; Federico Nichetti; Riccardo Lobefaro; Giorgia Peverelli; Francesca Ligorio; Emma Zattarin; Maria Silvia Cona; Pierangela Sepe; Francesca Corti; Sara Manglaviti; Marta Brambilla; Barbara Re; Antonino Belfiore; Giancarlo Pruneri; Luigi Celio; Gabriella Mariani; Giulia Valeria Bianchi; Licia Rivoltini; Giuseppe Capri; Filippo de Braud
Journal:  Cancers (Basel)       Date:  2020-03-06       Impact factor: 6.639

10.  Overexpression of HURP mRNA in head and neck carcinoma and association with in vitro response to vinorelbine.

Authors:  Ahmed S K Al-Khafaji; Paschalia Pantazi; Amelia Acha-Sagredo; Andrew Schache; Janet M Risk; Richard J Shaw; Triantafillos Liloglou
Journal:  Oncol Lett       Date:  2020-01-23       Impact factor: 2.967
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.